Variation of normal protein could be key to resistance to common cancer drug
Thursday, August 28, 2008 - 10:14
in Health & Medicine
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
Read the whole article on Physorg
More from Physorg
Related
- Variation of normal protein could be key to resistance to common cancer drugThu, 28 Aug 2008, 11:15:35 EDT
- Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapyThu, 26 Mar 2009, 14:30:30 EDT
- Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer CenterWed, 8 Oct 2008, 3:44:36 EDT
- New drug shows promise in treating drug-resistant prostate cancerFri, 10 Apr 2009, 10:24:39 EDT
- Identifying the potential for tamoxifen resistance in patientsWed, 10 Jun 2009, 16:43:34 EDT